Tolebrutinib, a brain-penetrant and bioactive Bruton tyrosine kinase inhibitor that modulates persistent immune activation ...

Results of the Phase III HERCULES trial suggest the first potential treatment option for a form of multiple sclerosis.

Tolebrutinib is an oral, brain-penetrant, and bioactive Bruton’s tyrosine kinase inhibitor that modulates peripheral ...

A Cleveland Clinic-led clinical trial of tolebrutinib, an investigational oral Bruton's tyrosine kinase inhibitor, a group of ...

Cogent Biosciences, Inc.’s COGT share price has dipped by 7.73%, which has investors questioning if this is right time to buy ...

Annual Meeting Clinical Trials Plenary Session, Sanofi presented data on tolebrutinib in patients with non-relapsing ...

A new study has unveiled when chronic myeloid leukemia, a type of cancer that affects the blood and bone marrow, arises in ...

A Cleveland Clinic-led clinical trial of tolebrutinib, an investigational oral Bruton's tyrosine kinase inhibitor, a group of drugs originally developed to treat lymphomas and related blood disorders, ...

Cogent Biosciences, Inc. topline results for phase 2/3 studies on bezuclastinib targeting systemic mastocytosis & GIST are ...

New research led by a St. Michael's Hospital clinician-scientist and published in the New England Journal of Medicine ...

Throughout the course of multiple sclerosis, gradually progressive neurologic impairment can occur, which has been called ...